

PharMerica CORP  
Form 8-K  
May 02, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 2, 2013

**PHARMERICA CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**001-33380**  
(Commission

File Number)

**87-0792558**  
(IRS Employer

Identification No.)

Edgar Filing: PharMerica CORP - Form 8-K

**1901 Campus Place**

**Louisville, Kentucky**  
(Address of principal executive offices)

**40299**  
(Zip Code)

**(502) 627-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On May 2, 2013, PharMerica Corporation (the Company ) held its quarterly earnings conference call. During the call certain analysts requested that the Company provide them with the number of prescriptions that were dispensed to one of Company s customers, Golden Living, during the first quarter of 2013. PharMerica dispensed approximately 781,800 prescriptions to Golden Living during the first quarter of 2013.

The information in this Item 7.01 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMERICA CORPORATION

Date: May 2, 2013

By: /s/ Thomas Caneris  
Thomas Caneris  
Senior Vice President, General Counsel, Compliance Officer and  
Secretary

3